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Aggregated alpha-synuclein inclusions are found
where cell death occurs in several diseases, in-
cluding Parkinson’s disease, dementia with Lewy
bodies, and multiple-system atrophy. However, the
relationship between inclusion formation and an indi-
vidual cell’s fate has been difficult to study with con-
ventional techniques. We developed a system that
allows for in vivo imaging of the same neurons over
months. We show that intracerebral injection of pre-
formed fibrils of recombinant alpha-synuclein can
seed aggregation of transgenically expressed and
endogenous alpha-synuclein in neurons. Somatic
inclusions undergo a stage-like maturation, with
progressive compaction coinciding with decreased
soluble somatic and nuclear alpha-synuclein. Mature
inclusions bear the post-translational hallmarks of
human Lewy pathology. Long-term imaging of in-
clusion-bearing neurons and neighboring neurons
without inclusions demonstrates selective degenera-
tion of inclusion-bearing cells. Our results indicate
that inclusion formation is tightly correlated with
cellular toxicity and that seeding may be a patholog-
ically relevant mechanism of progressive neurode-
generation in many synucleinopathies.INTRODUCTION
Evidence suggests that many neurodegenerative diseases
involve spreading aggregation of specific proteins through the
nervous system, potentially via a prion-like mechanism (for re-
view, see Jucker and Walker, 2013, Guo and Lee, 2014, and
Fraser, 2014). Synucleinopathies are such a group typified by
pathologically aggregated alpha-synuclein in specific neuronal
(e.g., Parkinson’s disease anddementiawith Lewybodies) or glial1252 Cell Reports 10, 1252–1260, March 3, 2015 ª2015 The Authors(e.g., multiple-system atrophy) populations where cell loss oc-
curs. Recent work demonstrates that aspects of progressive
alpha-synuclein aggregation can be recapitulated in model sys-
tems by exogenous introduction of in-vitro-generated, preformed
fibrils (PFFs) of alpha-synuclein (Volpicelli-Daley et al., 2011; Luk
et al., 2012a, 2012b;Masuda-Suzukake et al., 2013; Sacino et al.,
2014a, 2014b, 2014c). PFFs seed the aggregationof endogenous
alpha-synuclein, and this aggregation spreads along synaptically
connected pathways (Luk et al., 2012a, 2012b). One hypothesis
is that this seeding involves a prion-like mechanism where intro-
duced PFFs directly convert endogenous alpha-synuclein into an
aggregated form that then propagates through the brain. How-
ever, recent work questions the ability of PFFs to cause wide-
spread seeding of endogenous alpha-synuclein (Sacino et al.,
2014a) and other potential mechanisms for spreading have
been proposed (for review, see Brundin et al., 2008 and Golde
et al., 2013). In addition, the role inclusion development plays in
a cell’s ultimate fate has been difficult to determine using current
techniques. Evidence supporting either an association between
Lewy pathology development and compromised cell health (Lu
et al., 2005; Greffard et al., 2010) or the opposite, relative neuro-
protection (Gertz et al., 1994; Bodner et al., 2006; Tanaka et al.,
2004), exists in the literature.
To test these mechanisms in vivo, we developed a multi-
photon imaging approach to monitor conversion of endogenous
alpha-synuclein into pathologically aggregated states in living
mouse brain after PFF injection. Transgenic mice expressing
GFP-tagged wild-type (WT) human alpha-synuclein (Syn-GFP;
Rockenstein et al., 2005) were injected with mouse sequence
PFFs in primary sensory cortex and neuronal aggregation of
Syn-GFPmonitored in vivo usingmultiphotonmicroscopy. Serial
imaging of individual mice allowed us to determine the time
course and pattern of inclusion development up to 13months af-
ter PFF injection. In vivo multiphoton fluorescence recovery after
photobleaching (FRAP) experiments allowed us to measure
alpha-synuclein mobility in different somatic pools and detected
a slow alpha-synuclein turnover rate within inclusions. These
data suggest that exogenously introduced PFFs convert endog-
enous alpha-synuclein into an aggregated state structurally
similar to inclusions found in human disease. Our data further
suggest that aggregation is a stage-like process, with pro-
gressive compaction and coincident reduction in soluble cyto-
plasmic and nuclear levels as inclusions mature. Imaging of
individual neurons over months detected selective cell death of
inclusion-bearing neurons, suggesting a critical role for Lewy
pathology in a cell’s fate.
RESULTS
In Vivo Imaging Demonstrates a Stage-like, Progressive
Maturation of Syn-GFP Inclusions within Neurons
PFFs were injected into right hemisphere sensory cortex of mice
expressing Syn-GFP under control of the PDGF promoter. We
placed cranial windows starting at 2 months post-injection. At
this time point, the Syn-GFP expression pattern in neuronal cell
bodies and presynaptic terminals in PFF-injected animals was
unchanged from uninjected or PBS-injected controls (Figure 1A).
Our previous work demonstrated that somatic Syn-GFP is not
aggregated, does not spontaneously form inclusions, and is
freely diffusible in the absence of PFF injection (Unni et al.,
2010; Spinelli et al., 2014). Starting at2.5months post-injection,
Syn-GFP aggregates were readily apparent in neurites near the
injection site and rarely in the contralateral hemisphere of PFF-in-
jected mice (Figure 1B). At 3 months post-injection, individual
neurons near the injection site exhibited heterogeneous somatic
Syn-GFP staining, with parts of the same cell body containing
normal homogenous staining and other parts abnormal Syn-
GFP accumulations (Figure 1B). At4–13months post-injection,
somatic inclusions increased in frequency near the injection site
and took on a morphologically distinct character. Mature inclu-
sions often presented as a cytoplasmic Syn-GFP accumulation
(‘‘body’’) with tendrils (‘‘legs’’) that wrapped around the nucleus,
giving mature inclusions a ‘‘spider-like’’ appearance (Figure 1B).
Interestingly, unlike immature inclusions, at this later stage, there
was a decrease in the normal-appearing soluble Syn-GFP stain-
ing in the cytoplasm and nucleus, compared to earlier time points
(Figure 1B). Starting at 4 months post-injection, mature inclu-
sions were abundant in the contralateral left hemisphere as well
(Figure 1B). Quantitative analysis of Syn-GFP homogeneity
across cell bodies demonstrated a single population with low in-
homogeneity in all neurons from uninjected and PBS-injected
mice (Figure 1C). In contrast, PFF-injected mice at >3 months
post-injection showed two distinct populations: one with low in-
homogeneity (0.11 ± 0.03 inhomogeneity index; n = 56 cells/6
animals; Figure 1C) nearly identical to PBS-injected mice (0.10
± 0.03 inhomogeneity index; n = 69 cells/2 animals; one-way
ANOVA p < 0.0001; Tukey post hoc testing no significant differ-
ence for this comparison; Figure 1C) and a second population
with a significantly higher inhomogeneity (0.47 ± 0.16; n = 108
cells/7 animals; Tukey post hoc test p < 0.05; Figure 1C), corre-
sponding to neurons with spider-like inclusions (Figure 1C).
In Vivo Multiphoton FRAP Demonstrates Progressive
Compaction of Syn-GFP Aggregates
Multiphoton FRAP can be used to measure Syn-GFP mobility of
distinct pools in different subcellular compartments in vivo (Unni
et al., 2010; Spinelli et al., 2014). We used this technique to firstCemeasure the somatic immobile Syn-GFP fraction in PBS-injected
animals. All neurons demonstrated a low somatic immobile frac-
tion (11% ± 7%; n = 7 cells/2 animals; Figure 2C), consistent with
our previous work using in vivo multiphoton FRAP, Proteinase K
digestion, and immunohistochemistry demonstrating no spon-
taneous somatic aggregation (Spinelli et al., 2014). We next
performed FRAP on immature inclusions at 3 months post-
injection. Unlike in somata without aggregated Syn-GFP (in
PBS-injected controls), we detected a large immobile fraction
measured at 5 min post-bleach (70% ± 16%; n = 8 cells/3 ani-
mals; Figures 2A and 2C) that was significantly different than
somata without inclusions (one-way ANOVA p < 0.0001; Tukey
post hoc test p < 0.05; Figure 2C). In addition, simultaneous
bleaching of aggregated and unaggregated regions in a single
neuron demonstrated an immobile fraction only in the aggre-
gated region of the soma (Figure 2A). Similar FRAP experiments
performed in mature inclusions at 4–13 months post-injection
demonstrated an even larger immobile fraction (97% ± 6%;
n = 16 cells/4 animals; Figures 2A and 2C), significantly different
than both unaggregated regions and immature inclusions (one-
way ANOVA p < 0.0001; Tukey post hoc test p < 0.05 for both
comparisons; Figure 2C).
Chronic In Vivo Imaging Demonstrates a Low Molecular
Turnover Rate within Aggregates
We extended the timescale of our FRAP experiments to deter-
mine whether the fraction of Syn-GFP that is immobile on the mi-
nutes timescale recovers over longer time scales. These results
demonstrated that a partial Syn-GFP fluorescence recovery
within the bleached region does occur over 7 days (immobile
fraction 5 min: 97% ± 6%, n = 16 cells/4 animals; immobile frac-
tion 7 days: 49% ± 17%, n = 10 cells/3 animals; one-way ANOVA
p < 0.0001; Tukey post hoc test p < 0.05; Figures 2A–2C), corre-
sponding to a 49% decrease in the previously immobile fraction.
This indicates that there is a slow turnover of Syn-GFP within in-
clusions and that unbleached protein, either newly synthesized
or from unbleached regions, moves into the bleached region
and becomes incorporated over the course of several days.
Mature Somatic InclusionsBear theHallmarks of Human
Lewy Pathology
Mice were sacrificed and brains fixed for immunohistochemistry
at multiple time points following PFF injection. Starting at
1 months post-injection, we detected abnormal Syn-GFP ac-
cumulations in cortical neuron cell bodies in the right (injected)
hemisphere and neurites with an axonal appearance in cortical
layers (V/VI), deeper than we can image in vivo, whereas similar
accumulationswere not seen in the cortex of PBS-injected or un-
injected controls (data not shown), consistent with our in vivo im-
aging results (Figure 1) and our previous work (Spinelli et al.,
2014). Starting at3months post-injection, numerous inclusions
were detectible (Figure 3) in more superficial layers (II/III), with the
same mature, spider-like appearance imaged in vivo from these
same cortical layers (Figure 1). These inclusions bore all the hall-
marks of human Lewy pathology, including significant alpha-syn-
uclein phosphorylation at serine-129 (Figures 3A1–3A4, 3B1, and
3B2), amyloid dye binding (thioflavin S and X-34; Figures 3A1
and 3A2), and ubiquitination (Figure 3A3). Importantly, numerousll Reports 10, 1252–1260, March 3, 2015 ª2015 The Authors 1253
Figure 1. In Vivo Imaging Demonstrates a Stage-like, Progressive Maturation of Syn-GFP Inclusions within Neurons
(A) In vivo imaging in cortex layer II/III of uninjected (left), saline-injected (middle), or PFF-injected (right) animals at 2months post-injection demonstrates punctate
presynaptic staining within the neuropil and only homogenous somatic Syn-GFP staining within neurons. The scale bar represents 10 mm.
(B) Top: starting at 2.5months post-injection, imaging near the PFF injection site demonstrates frequent neuritic Syn-GFP aggregates in layer II/III and rare neuritic
aggregates in the contralateral hemisphere in the symmetric location to the injection. Schematic representation shows injection location in the right hemisphere
(X), extent of cranial window (dashed circle), and location of neuritic aggregates (blue dot). The scale bar represents 10 mm.Middle: at 3 to 4months post-injection,
neurons (green dot in schematic) near the injection site began showing both disorganized somatic Syn-GFP inclusions and normal homogenous staining. The
scale bar represents 10 mm. Bottom: at 4–13months post-injection, only mature, organized somatic and neuritic Syn-GFP inclusions are present. Mature somatic
inclusions have a stereotyped appearance, often with a single juxtanuclear accumulation and legs that wrap around the nucleus, giving a ‘‘spider-like’’
appearance. The normal homogenous somatic and nuclear Syn-GFP staining is absent in neurons containingmature inclusions. Schematic representation shows
location of numerous mature somatic inclusions (red dot) near the injection site and in the contralateral hemisphere. The scale bar represents 10 mm.
(C) Example of two neurons (C1), one with normal homogeneous staining and one with a mature inclusion, and transect ROIs used to measure fluorescence (C2)
across the cell body. An inhomogeneity index was calculated (see Experimental Procedures) and used to measure the mean index value (C3) in neurons from
uninjected, saline-injected, and PFF-injected animals with and without inclusions. Neurons from uninjected, saline-injected, and PFF-injected animals without
inclusions show low levels of inhomogeneity, whereas inclusion-bearing neurons from PFF-injected animals were significantly more inhomogeneous. n = cells/
animals. Histogram of inhomogeneity index values from cells from all three groups (C4) shows single populations with low inhomogeneity in uninjected and saline-
injected animals, whereas PFF-injected animals show two distinct populations: a low-index one nearly identical to saline-injected animals and a high-index
population corresponding to neurons with mature somatic inclusions. The scale bar represents 10 mm. All error bars show SD.similar inclusions composed only of untagged endogenous
mouse alpha-synuclein with the same morphology and staining
characteristics (Figure 3A5) were found in nearby Syn-GFP-nega-
tive cells, strongly suggesting that the GFP tag does not interfere1254 Cell Reports 10, 1252–1260, March 3, 2015 ª2015 The Authorswith the mechanism of Lewy pathology formation. Staining with
an anti-GFP antibody demonstrated that the green fluorescent
inclusionsweremade of Syn-GFP and not an endogenous, green
autofluorescent species or autofluorescence from the injected
Figure 2. In Vivo FRAP Demonstrates Progressive Compaction of and a Low Molecular Turnover Rate within Syn-GFP Inclusions
(A) Individual neuron (A1) with an immature inclusion at 3 months post-injection demonstrates mixed aggregated and unaggregated somatic Syn-GFP staining
pattern. Two ROIs, one within (green circle) and one outside (black circle) the aggregated portion, are photobleached simultaneously and sequential images
shown before and after FRAP. Bleach pulse occurs just before time 0. The scale bar represents 5 mm. Similar FRAP experiment of the aggregated portion (red
circle) of a mature inclusion (A2) at >4 months post-injection. The scale bar represents 5 mm. Mean fluorescence intensity (A3) from the three ROIs from the two
cells in (A1) and (A2) plotted on the same timescale demonstrates complete recovery back to baseline of the homogeneous staining but large immobile fractions in
the immature and mature inclusions.
(B) Individual neuron (B1) with a mature somatic inclusion at 4 months post-injection and absent unaggregated Syn-GFP staining in the remaining cytoplasm or
nucleus. ROI (red rectangle) shows part of inclusion that was photobleached. The scale bar represents 7 mm. Mean intensity from this ROI over time (B2) shows a
large immobile fraction at 5–10 min post-bleach, which recovers substantially at 7 days post-bleach.
(C) Group data comparingmeasured immobile fractions from unaggregated somatic Syn-GFP, immature andmature inclusions at 5min post-bleach, andmature
inclusions 7 days post-bleach, showing a significant progressive increase in the immobile fraction from immature to mature inclusions as measured at 5 min. At
7 days post-bleach, however, 49% of the previously immobile fraction recovers, demonstrating a slow turnover of protein within inclusions. n = cells/animals. All
error bars show SD.material itself (Figures 3A4 and 3B1). Further evidence for this
came from PFF injections in non-transgenic animals, which did
not exhibit any green fluorescent inclusions (Figure S1), also
demonstrating that the Lewy pathology we image in vivo and in
fixed tissue is composed of Syn-GFP and not autofluorescent
species. Quantification of Syn-GFP levels within inclusions
versus neighboring Syn-GFP-positive neuronswithout inclusionsCedemonstrated a significant, large increase in Syn-GFP protein
within mature Lewy inclusions (17 ± 11-fold increase; n = 25
cell pairs/3 animals; p < 0.0001; paired t test; Figure 3B). Syn-
GFP within inclusions was also significantly more colocalized
with phospho-synuclein forms than Syn-GFP in cells without
inclusions (average Pearson’s coefficient within inclusions: 0.66
± 0.19, n = 22 cells/3 animals; without inclusions: 0.03 ± 0.02,ll Reports 10, 1252–1260, March 3, 2015 ª2015 The Authors 1255
Figure 3. Mature Somatic Inclusions Bear the Hallmarks of Human Lewy Pathology
(A)Mature Syn-GFP inclusions are heavily phosphorylated at serine-129 (A1–A4), in an amyloid dye binding configuration (A1 andA2) and ubiquitinated (A3). The green
fluorescence from these inclusions is due to the presence of Syn-GFP and not an endogenous autofluorescent species, because they colabel with antibody to GFP
(A4). Similar mature inclusions made only of untagged endogenous mouse alpha-synuclein (A5) are also present in nearby neurons that do not express Syn-GFP.
These inclusions share a similar morphology and modification state to Syn-GFP-positive ones. Syn-GFP levels within mature inclusions (B, arrow) are greatly
increased over levels of the protein in nearby neurons without inclusions (arrowhead). Colocalization of Syn-GFPwith serine-129 phosphorylated alpha-synuclein
(B) is also increased in inclusions versus cells without inclusions. n = cells/animals.
(C) Individual neurons from human frontal cortex in cases of dementia with Lewy bodies (C) are stained with hematoxylin to outline the nuclei in blue and for serine-
129 phospho-synuclein aggregates in brown. Two examples demonstrate wrapping of aggregated alpha-synuclein around the nucleus (C1 andC2), similar to that
seen in mature mouse inclusions. Two other examples show ‘‘legs’’ of the inclusion that wrap around the nucleus (C3 and C4, black arrowhead), also similar to
mature mouse inclusions.
The scale bar represents 5 mm. See also Figures S1 and S2. All error bars show SD.n = 22 cells/3 animals; p < 0.0001; t test; Figure 3B). Sagittal sec-
tions of the injected right hemisphere also demonstrated the
presence of cortical and hippocampal inclusions, composed
either of Syn-GFP or endogenous mouse alpha-synuclein, at
and distant to the injection site along the anterior-posterior axis
of the cortex (Figure S2).
Aggregated Cortical Alpha-Synuclein Pathology
in Human Dementia with Lewy Bodies Cases Is
Structurally Similar to Mature Mouse Aggregates
Imaged In Vivo
Review of alpha-synuclein inclusion pathology stained for
serine-129 phospho-forms in frontal cortex in three cases of de-1256 Cell Reports 10, 1252–1260, March 3, 2015 ª2015 The Authorsmentia with Lewy bodies revealed numerous somatic inclusions
that wrapped around the nucleus with a similar morphology to
what we observe with our Syn-GFP inclusions in vivo (Figures
3C1 and 3C2). No staining was seen in a review of three age-
matched control cases without clinical evidence of dementia
(data not shown). In addition, frequent cortical inclusions were
found with tendrils of aggregated alpha-synuclein wrapping
around the nucleus (Figures 3C3 and 3C4), again similar to our
mature Syn-GFP inclusions in mice.
Selective Degeneration of Inclusion-Bearing Neurons
Serial imaging of individual inclusion-bearing and non inclusion-
bearing neurons over the course of 7 months detected a high
Figure 4. Chronic In Vivo Imaging Demonstrates Selective Degeneration of Inclusion-Bearing Neurons
(A and B) Field of neurons imaged 1 week apart demonstrate blood vessels by their negative stain, multiple neurons without inclusions, and three mature in-
clusion-bearing neurons (white square and arrowhead) on day 0. The scale bar represents 20 mm.
(C–E) One of these neurons (white square) degenerates by day 7 and is shown at higher power (C1). The scale bar in (C1) represents 10 mm and in (C2)–(E2)
represents 5 mm. Chronic imaging of individual neurons over months shows degeneration of some inclusion-bearing cells (C) with persistence of other cells with
(D) and without (E) inclusions.
(F–H) Group data (F) show selective degeneration of inclusion-bearing neurons over 7months. Schematic showing the loss of neurons in brain regions affected by
Parkinson’s diseasewith the presence of Lewy pathology (red circle) in some of the remaining cells (G) and two different models for how this same final statemight
arise (H). One model posits a positive correlation between Lewy pathology presence and cell death, whereas the other an inverse correlation.rate of disappearance of mature Lewy inclusion-bearing cells
(40.3% survival at 207 days; n = 154 cells/4 animals; Figures
4A–4D). In contrast, adjacent neurons without inclusions had a
very low rate of disappearance (99.4% survival at 207 days;
n = 272 cells/4 animals; Figures 4A, 4B, and 4E). This is similar
to our previous work demonstrating an undetectable rate of
loss of Syn-GFP-expressing neurons (100% survival of 42 cells)
in uninjected animals over 49 days (Unni et al., 2010). Survival
analysis showed that the presence of mature inclusions was
strongly correlated with cell death in the bearing neurons, with
a median survival of 113 days (p < 0.0001; Mantel-Cox test; Fig-
ure 4F). In addition, we did not detect large-scale changes in theCeshape of inclusions, even if they persisted for several months
(Figure 4D).
DISCUSSION
We have shown that the intracortical injection of mouse WT
alpha-synuclein PFFs into mice expressing human WT alpha-
synuclein tagged with GFP leads to the conversion of the trans-
genically expressed protein into neuritic and somatic inclusions
that bear the hallmarks of human Lewy pathology. Previous work
has questioned whether PFFs can seed widespread conversion
of alpha-synuclein into an aggregated form when it does notll Reports 10, 1252–1260, March 3, 2015 ª2015 The Authors 1257
contain the A53T point mutation (Sacino et al., 2014a). Specif-
ically, cross-reactivity between phospho-serine-129 synuclein
antibodies and neurofilament-L was suggested as the source
of signal interpreted as alpha-synuclein aggregates in other ex-
periments. In this work (Sacino et al., 2014a), alpha-synuclein
aggregates were only seen distant from injection site in animals
expressing the A53T point mutant, although more recent work
from the same group does show some evidence of spreading
human WT alpha-synuclein aggregation (Sacino et al., 2014c).
Our work uses a parallel approach to detect aggregated alpha-
synuclein based on endogenous GFP fluorescence. Both in fixed
tissue and with in vivo multiphoton imaging, we detect a time-
dependent, progressive aggregation of WT human Syn-GFP
only after PFF injection and not in controls. In addition, injections
localized to sensory cortex in one hemisphere produced a clear
spread of aggregation to the contralateral sensory cortex 3 to
4 months post-injection. These results, taken together with pre-
vious work (Luk et al., 2012a, 2012b; Masuda-Suzukake et al.,
2013), suggest that PFFs can seed progressive aggregation of
endogenous protein within brain that is not an artifact of antibody
cross-reactivity.
Our work is the first, to our knowledge, to examine formation of
alpha-synuclein inclusions in vivo within neurons of individual
animals over time. This chronic imaging demonstrates that inclu-
sions undergo a stage-like maturation starting from early aggre-
gates with disordered morphology alongside normal soluble so-
matic and nuclear Syn-GFP. Over the course of weeks, however,
inclusions change to become organized and compacted into
mature forms that resemble human cortical pathology in demen-
tia with Lewy bodies. Previous work from cross-sectional studies
of human tissue has demonstrated various forms of somatic in-
clusions that appear less compact than classical Lewy bodies,
such as cloud-like inclusions and pale bodies (Dale et al.,
1992; Go´mez-Tortosa et al., 2000). Several groups have postu-
lated that individual aggregates could undergo progressive
compaction along a pathway from diffuse aggregates to more-
compact Lewy bodies (Dale et al., 1992; Go´mez-Tortosa et al.,
2000; Wakabayashi et al., 2013). Alternatively, these structures
could reflect distinct parallel pathways (Dale et al., 1992). Our
work confirms that inclusion maturation can occur in vivo, with
progressive compaction as measured by FRAP. It will be impor-
tant in the future to determine what mechanisms underlie this
process.
In parallel with inclusion maturation, we measured a reduction
in soluble cytoplasmic and nuclear Syn-GFP in vivo. It is inter-
esting to speculate about the significance of this reduction,
because, although a nuclear role for synucleins has been sug-
gested since their initial discovery (Maroteaux et al., 1988), it is
less well understood. Specific activities involving intranuclear
alpha-synuclein have been recently proposed (Desplats et al.,
2011; Liu et al., 2011; Ma et al., 2014), and it may be that loss
of nuclear alpha-synuclein when inclusions mature contributes
to cellular dysfunction through a loss-of-function mechanism.
This would be in parallel to the better-established toxic, gain-
of-function consequences of alpha-synuclein aggregation.
Our work strongly suggests that inclusion-bearing neurons
selectively degenerate over the course of months, whereas
non inclusion-bearing neurons that express soluble Syn-GFP1258 Cell Reports 10, 1252–1260, March 3, 2015 ª2015 The Authorshave a much-lower rate of degeneration. This addresses a crit-
ical question in the field about the relationship between Lewy pa-
thology formation in individual neurons and their ultimate fate.
Although it is clear that Lewy pathology is found in regions where
progressive cell death occurs (Fearnley and Lees 1991; Parkki-
nen et al., 2011; Figure 4G), different models have been pro-
posed (Figure 4H), including oneswhere Lewy pathology is asso-
ciated with death of the containing cell (Lu et al., 2005; Greffard
et al., 2010), or the opposite, where Lewy pathology is associ-
ated with sparing of cell (Gertz et al., 1994; Bodner et al., 2006;
Tanaka et al., 2004). Our work suggests that the former model
is correct and that Lewy pathology formation is strongly associ-
ated with degeneration of the inclusion-bearing cell and not pro-
tection (Figure 4H). This argues that Lewy pathology formation it-
self could play an intimate role in neuronal cell loss, but more
work is needed to test this hypothesis, including methods to
selectively label the subgroup of neurons that take up PFFs.
This could be used to determine what fraction of neurons that
take up PFFs go on to form Lewy pathology. Then, by manipu-
lating Lewy pathology to increase or decrease its formation, it
should be possible to test whether the statistical association
that we have measured for the first time in vivo is due to a causal
role for Lewy pathology in cell death or whether more-compli-
cated mechanisms are at play and inclusion formation is actually
protective or simply neutral. The injection of other forms of alpha-
synuclein (e.g., monomeric and non-fibrillar aggregates) and
other amyloidogenic proteins (e.g., tau and beta-amyloid) to
test their ability to seed Lewy pathology formation is also of inter-
est for future work in this system, where potential cross-seeding
can be studied in individual neurons in vivo.
Overall, our work demonstrates that PFFs can seed progres-
sive conversion of endogenous alpha-synuclein into neuronal in-
clusions that bear the hallmarks of human disease and lead to
selective neuronal degeneration. This system provides a new,
in vivo model for testing mechanisms of alpha-synuclein inclu-
sion formation, neuronal cell loss, and potential pathways to
halt neurodegeneration in clinically important synucleinopathies.
EXPERIMENTAL PROCEDURES
Animals
Syn-GFP (PDNG78; Rockenstein et al., 2005) heterozygous male mice were
mated to BDF1 females (Charles River Laboratories) and housed by OHSU’s
DCM. Animals were held in a light-dark cycle and temperature- and humidi-
ty-controlled vivarium and maintained under ad libitum food and water diet.
All experiments were approved by the OHSU IACUC, and every effort was
made to minimize the number of animals used and their suffering.
Humans
Human subjects were seen in the Oregon Alzheimer’s Disease Center (ADC),
and affected subjects had established clinical diagnosis of dementia. Brain au-
topsy from three patients diagnosed with dementia with Lewy bodies between
the ages of 68 and 79 years and three age-matched control cases without clin-
ical evidence of neurodegenerative disease was performed in the ADC neuro-
pathology core. Tissue use was approved by the IRB at OHSU.
Intracerebral Injections and Immunohistochemistry
2- to 3-month-old Syn-GFP mice were injected with mouse WT sequence
PFFs, with PBS, or were uninjected controls. Injections were done according
to published protocols for PFF generation and preparation (Luk et al., 2012b)
and sensory cortex injections (Kuchibhotla et al., 2008). Briefly, 2.5 ml
(2 mg/ml) freshly sonicated PFFs or 2.5 ml PBS was injected into right hemi-
sphere primary sensory in isoflurane (1% to 2%)-anesthetized animals. For
IHC studies, whole brains were dissected and the cerebellum removed. Brains
were prepared and imaged using published protocols (Spinelli et al., 2014).
Briefly, hemispheres were placed in scintillation vials with 4% paraformalde-
hyde and fixed using a BioWave (Pelco) microwave fixation system. Hemi-
spheres were postfixed in 4% paraformaldehyde overnight at 4C and then
stored in PBS containing sodium azide (0.05%) until use. pSer129 aSyn
(81A; 1:667 dilution; Waxman andGiasson, 2008), ubiquitin (Z0458; 1:200 dilu-
tion; Dako), and GFP (AB6556; 1:500 dilution; Abcam) primary antibodies were
diluted in blocking buffer and slices incubated overnight at 4C. Appropriate
secondary antibodies (Alexa Fluor 647, Alex Fluor 555; 1:1,000; Invitrogen)
were incubated overnight at 4C. Thioflavin S and X-34 staining was performed
using standard techniques (Styren et al., 2000). Brain slices were mounted in
CFM-2 (Ted Pella), sealed with CoverGrip (Biotium), and allowed to dry over-
night in the dark. For confocal imaging, sections were imaged on a Zeiss
LSM710 confocal microscope with a Plan-Apochromat 633/1.40 oil objective.
Fluorescence images were analyzed in Fiji (Schindelin et al., 2012) or ImageJ
(NIH) with only linear scaling of pixel values. Human neuropathological analysis
was done using standard hematoxylin methods. Standard IHC methods were
used to evaluate serine-129-phosphorylated alpha-synuclein. In brief,
formalin-fixed, paraffin-embedded sections of frontal cortex were incubated
with antibody EP1536Y (1:10,000; Abcam), developed with diaminobenzidine
chromagen, and counterstained with hematoxylin, as previously described
(Leverenz et al., 2008).
Cranial Window Surgery and Imaging
Starting at 2 months post-injection, cranial window surgery was performed
and in vivo imaging and photobleaching begun similar to published protocols
(Spinelli et al., 2014). Isoflurane-anesthetized animals were placed in a
custom-built stereotaxic frame and surgery performed to create an 5-mm-
diameter midline circular craniotomy between bregma and lambda, closed
with 8 mm cover glass, and a custom-built aluminum fixation bar cemented
into place. On imaging days, isoflurane-anesthetized animals were mounted
into the stereotaxic frame and imaged using a Zeiss LSM 7MPmultiphotonmi-
croscope outfitted with dual channel BiG (binary GaAsP) detectors and a
Coherent Technologies Chameleon titanium-sapphire femtosecond pulsed
laser source (tuned to 860 nm). Zeiss Zen 2011 image acquisition software
was used.
Imaging Analysis
Images were analyzed with ImageJ or Fiji (Schindelin et al., 2012) as previously
described (Spinelli et al., 2014). Briefly, regions of interest (ROIs) were selected
to obtain mean fluorescence values in relevant ROIs. The inhomogeneity index
was calculated as the average root-mean-square deviation of the normalized
fluorescence signal across a transect of the cell body. FRAP data were
analyzed in Prism 5 (GraphPad) to obtain single exponential fits to the recovery
time course and the immobile and mobile fractions. For chronic inclusion
imaging >1 day, individual bleached ROI intensities were normalized to un-
bleached regions to control for possible differences in imaging conditions pre-
sent on different days.
Statistics
All data are reported as the mean ± SD. Numbers and statistical tests used are
reported in relevant sections.
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